Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Common Stock Issued
Cash raised by issuing new shares.
Immunome, Inc.NASDAQ: IMNM
Common Stock Issued · Q3 FY2026 · quarter ended Sep 2026
Common stock issued turns negative
Q3 FY2026 common stock issued was -$923K, compared with $45.39M a year earlier. Trailing-twelve-month common stock issued was $432.8M. Over 3 fiscal years it compounded at +2614.9% a year.
Context
- Common stock issued amounted to 9225.7% of revenue in FY2025, up 6460.5 pp from a year earlier.
- Common stock issued increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near -$923K or moves back toward the trailing-twelve-month quarterly average of $108.2M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 640.36M USD
- Year-over-year change
- +156.1%
- 4-year CAGR
- +120.2%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 640.36M | +156.1% |
| FY2024 | 2024-12-31 | 250M | +735200.0% |
| FY2023 | 2023-12-31 | 34K | +6.3% |
| FY2022 | 2022-12-31 | 32K | -99.9% |
| FY2021 | 2021-12-31 | 27.23M | — |
Common Stock Issued vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +90.2% is the 6th highest of 10, against a peer median of +118.9%.
- Over three fiscal years its annual growth of +2614.9% compares with a peer median of -16.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $432.8M USD | +90.2% | +2614.9% | — | |
| LTM Sep 2026 | $327.45M USD | +22878.8% | -16.3% | 292364.3% | |
| LTM Mar 2026 | $251.58M USD | +3182.6% | +4561.9% | — | |
| LTM Mar 2026 | $226.9M USD | +360.2% | — | — | |
| LTM Mar 2026 | €121.46M EUR | -27.9% | -10.5% | 325.7% | |
| LTM Sep 2026 | $118.15M USD | +118.9% | +53.5% | — | |
| LTM Mar 2026 | $107.36M USD | — | +216.5% | — | |
| LTM Mar 2026 | $103.37M USD | +5.6% | -81.2% | 103.8% | |
| LTM Mar 2026 | $9.41M USD | +160.6% | -59.6% | 2.4% | |
| LTM Mar 2026 | $140K USD | -82.4% | -50.8% | 0.1% | |
| LTM Mar 2026 | $9.99K USD | -100.0% | -81.3% | 0.0% | |
| Peer median (excluding IMNM) | — | +118.9% | -16.3% | 53.1% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| Deferred Income Tax | (500K) | (7.27M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.45M | 5.33M | 6.22M | 15.75M | 25.69M |
| Change in Working Capital | 2.78M | 2.24M | 12M | 14.87M | (15.23M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.78M | (677K) | (608K) | 9.53M | (9.16M) |
| Other Working Capital | 998K | 2.92M | 12.61M | 5.35M | (6.06M) |
| Other Non-Cash Items | 4K | 7.27M | 80.29M | 149.45M | 8.06M |
| Operating Cash Flow | (18.23M) | (28.69M) | (7.57M) | (110.79M) | (190.92M) |
| Capital Expenditures | (79K) | (248K) | (831K) | (53.51M) | (9.69M) |
| Acquisitions (Net) | 0 | 0 | 9.28M | 0 | 0 |
| Purchases of Investments | 0 | 0 | (38.93M) | (186.56M) | (123.27M) |
| Sales of Investments | 0 | 0 | 0 | 155M | 200M |
| Other Investing Activities | 0 | 0 | 0 | (46.34M) | (6.25M) |
| Investing Cash Flow | (79K) | (248K) | (30.48M) | (85.06M) | 60.8M |
| Debt Repayment | (113K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.23M | 32K | 34K | 250M | 640.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 656K | 0 | 116.37M | (9.47M) | 0 |
| Financing Cash Flow | 27.77M | 32K | 116.41M | 240.53M | 640.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.46M | (28.91M) | 78.36M | 44.67M | 510.24M |
| Free Cash Flow | (18.31M) | (28.94M) | (8.4M) | (164.3M) | (200.6M) |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.